Autologous CMV-specific cytotoxic T cell therapy (MD Anderson Cancer Center)

N/A

Report date: 2024/05/13 20:00:33

Base Information

Drug NameAutologous CMV-specific cytotoxic T cell therapy (MD Anderson Cancer Center)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Cytotoxic T-lymphocytes therapy

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsLymphomaLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesThe University Of Texas MD Anderson Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesThe University Of Texas MD Anderson Cancer Center

Active IndicationsN/A

Inactive IndicationsLymphomaLeukemia

Other Information

ATC CodeN/A